AnPac Bio-Medical Science Co., Ltd.
ANPC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $12 | $18 | $21 | $11 |
| % Growth | -33% | -12.3% | 89.1% | – |
| Cost of Goods Sold | $4 | $6 | $8 | $6 |
| Gross Profit | $8 | $12 | $13 | $5 |
| % Margin | 69.2% | 68.1% | 62.8% | 44.2% |
| R&D Expenses | $10 | $16 | $12 | $10 |
| G&A Expenses | $71 | $81 | $75 | $71 |
| SG&A Expenses | $83 | $102 | $94 | $84 |
| Sales & Mktg Exp. | $12 | $21 | $20 | $14 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $92 | $118 | $106 | $94 |
| Operating Income | -$84 | -$106 | -$93 | -$89 |
| % Margin | -698.6% | -589.6% | -454.1% | -821.4% |
| Other Income/Exp. Net | -$22 | -$9 | $14 | -$13 |
| Pre-Tax Income | -$106 | -$121 | -$81 | -$102 |
| Tax Expense | -$2 | -$1 | -$0 | -$0 |
| Net Income | -$104 | -$120 | -$81 | -$102 |
| % Margin | -860.2% | -667.7% | -392.8% | -937% |
| EPS | -54.18 | -176.53 | -143.99 | -205.96 |
| % Growth | 69.3% | -22.6% | 30.1% | – |
| EPS Diluted | -54.18 | -176.53 | -143.99 | -205.96 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $4 | $1 | $3 |
| Depreciation & Amortization | $6 | -$4 | $16 | -$4 |
| EBITDA | -$100 | -$112 | -$77 | -$93 |
| % Margin | -827.1% | -623.2% | -377.5% | -860.7% |